Lilly, Novo Nordisk closer to deal with Trump administration to slash obesity drug prices to $149/month
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
The integration of AHG’s specialized cold chain transportation and third-party logistics (3PL) solutions will significantly strengthen UPS Healthcare’s service offerings
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Subscribe To Our Newsletter & Stay Updated